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Abstract
Background: 209 000 new cases of renal carcinoma are diagnosed each year worldwide and new therapeutic
targets are urgently required. The great majority of clear cell renal cancer involves inactivation of VHL, which acts
as a gatekeeper tumour suppressor gene in renal epithelial cells. However how VHL exerts its tumour suppressor
function remains unclear. A gene expression microarray comparing RCC10 renal cancer cells expressing either VHL
or an empty vector was used to identify novel VHL regulated genes.
Findings: NMU (Neuromedin U) is a neuropeptide that has been implicated in energy homeostasis and tumour
progression. Here we show for the first time that VHL loss-of-function results in dramatic upregulation of NMU
expression in renal cancer cells. The effect of VHL inactivation was found to be mediated via activation of Hypoxia
Inducible Factor (HIF). Exposure of VHL expressing RCC cells to either hypoxia or dimethyloxalylglycine resulted in
HIF activation and increased NMU expression. Conversely, suppression of HIF in VHL defective RCC cells via siRNA
of HIF-a subunits or expression of Type 2C mutant VHLs reduced NMU expression levels. We also show that renal
cancer cells express a functional NMU receptor (NMUR1), and that NMU stimulates migration of renal cancer cells.
Conclusions: These findings suggest that NMU may act in an autocrine fashion, promoting progression of kidney
cancer. Hypoxia and HIF expression are frequently observed in many non-renal cancers and are associated with a
poor prognosis. Our study raises the possibility that HIF may also drive NMU expression in non-renal tumours.
Findings
Kidney cancer is responsible for 102 000 deaths per year
worldwide and prognosis is generally poor [1]. Clear cell
renal cell carcinoma (CCRCC) is the commonest form
of kidney cancer and the von Hippel-Lindau (VHL)
tumour suppressor gene is mutated or inactivated in the
vast majority of these tumours [2]. Mutations in VHL
also underlie the familial renal cancer syndrome VHL
disease [3]. In addition to CCRCCs, patients with VHL
disease are also predisposed to phaeochromocytomas,
haemangioblastomas of the central nervous system and
retina and cysts affecting a variety of organs including
the kidney and pancreas [2]. Although much has been
learnt about VHL in recent years, its tumour suppressor
function is still not fully understood.
There has been considerable success in developing
new treatments for CCRCC that target aspects of the
pathways related to loss of VHL function [1]. As a strat-
egy to identify further potential targets, we examined
the effect of re-expressing VHL in RCC10 renal cancer
cells [4]. This cell background is attractive because re-
expression of VHL alone restores many aspects of nor-
mal epithelial cell behaviour, including formation of
tight junctions [5,6], adherens junctions [7,8] and a pri-
mary cilium [9-11]. Three separate pools of RCC10 VHL
defective CCRCC cells were transduced with retro-
viruses expressing wild-type VHL; in parallel three pools
were transduced with an empty vector. A substantial
number of genes showed highly significant differences in
expression, including many known to be modulated by
VHL status (Figure 1A).
The neuropeptide Neuromedin U (NMU) was selected
as being of particular interest for the following reasons.
First, it was amongst the most highly regulated genes
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and has not previously been identified as modulated by
VHL. Second, it acts on two identified G-protein
coupled receptors making it potentially pharmacologi-
cally tractable [12]. Third, it has been implicated in
autocrine growth and epithelial to mesenchymal transi-
tion in cancer [13]. Fourth, as a secreted peptide NMU
may offer potential as a circulating or urinary biomarker
in CCRCC. Recently Ketterer et al. showed that serum
levels of NMU decrease following pancreas resection of
pancreatic cancer patients [14].
NMU is a potent neuropeptide which was originally
discovered in the 1980’s. In humans NMU gives rise to
a biologically active icosapentapeptide (NMU-25); func-
tion is dependent on a highly conserved C terminal
sequence which is subject to enzymatic amidation. Sev-
eral biological functions have been ascribed to NMU
including regulation of smooth muscle contraction,
blood pressure and local blood flow, ion transport in the
gut, stress responses, gastric acid secretion, nociception
and feeding behaviour [12,15,16].
To confirm the effect of VHL status on NMU expres-
sion that we observed on microarray analysis of retrovi-
rally transduced pools of RCC10 cells, we next
examined NMU expression in RCC10 cells and a subline
stably expressing wild-type VHL (RCC10/VHL). We also
examined a second VHL defective renal cancer cell line
and subline expressing VHL derived from a different
patient (RCC4 and RCC4/VHL). As expected, VHL sup-
pressed HIF-a protein levels (Figure 1B) and mRNA
expression of the HIF target gene PHD3 (Figure 1C) in
both cell backgrounds. Real time RT-PCR analysis
showed NMU mRNA expression was markedly
increased in the absence of functioning VHL in both
RCC10 and RCC4 cells (Figure 1C).
Several different biochemical functions have been
reported for VHL including regulation of microtubule
stability, cell differentiation, cell motility, extracellular
matrix assembly, JunB and atypical isoforms of protein
kinase C [2]. However the most extensively studied
function of VHL is regulation of HIF [17]. HIF is com-
prised of a constitutively active b subunit and an oxy-
gen-regulated a subunit. In the presence of oxygen the
a-subunit is hydroxylated by a group of prolyl hydroxy-
lase domain (PHD) enzymes, leading to capture by
VHL, ubiquitination and proteosomal destruction
[17-19]. In hypoxia (or if VHL is inactivated) HIF a is
Figure 1 VHL regulates expression of Neuromedin U. A) RCC10 retroviral cell pools infected with empty vector or expressing wild-type VHL
were prepared as described previously [7]. Cells were cultured for 48 hours and RNA expression analysed using an Affymetrix U133 Plus 2.0
human gene expression array. Microarray analysis identified differentially expressed genes by comparing expression levels in VHL defective cells
to expression in VHL expressing cells. The five most highly upregulated and down-regulated genes, including NMU are listed in 1a. B) Protein
lysates were prepared from VHL defective RCC10 and RCC4 cell lines and sub-lines stably expressing VHL and samples run on a SDS Page gel.
Membranes were probed with HIF-1a (BD, San Diego, CA), HIF-2a (Novus Biologicals, Littleton, CO) and a-tubulin (Sigma, St. Louis, MO). In the
absence of VHL both HIF-1a and HIF-2a are clearly detected, however in the presence of VHL levels of both HIF-1a and HIF-2a are suppressed.
Equal levels of a-tubulin confirm equivalent loading. C) Real-time RT PCR analysis for NMU and the HIF target gene PHD3 was performed using
SYBR-Green PCR Master Mix (Abgene, Epsom, United Kingdom). Data presented here has been normalised to expression of b-actin. Cell lines
expressing VHL show marked suppression of NMU and PHD3 compared to VHL defective cell lines (*p < 0.01, using student’s T test). (Primers:
NMU For: 5’-CCTCAAGGATTACAGCCTG-3’, NMU Rev: 5’-GTTCCTGAGGCTTTGGTAG-3; PHD3 For F 5’-GATGCTGAAGAAAGGGC-3’, PHD3 Rev R 5’-
CTGGCAAAGAGAGTATCTG-3’; b-actin For 5’-CCCAGAGCAAGAGAGAGG-3’, b-actin Rev 5’-GTCCAGACGCAGGATG-3’).
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stabilised. HIF is a master regulator of oxygen homeos-
tasis and drives the transcriptional upregulation of >100
genes involved in processes such as glucose transport,
glycolysis and angiogenesis, which collectively allow the
adaption of the cells, tissues and organisms to low oxy-
genation [2,17,18].
To investigate whether activation of HIF mediates the
high expression of NMU we exposed RCC10 cells stably
expressing VHL to hypoxia as a means of activating
HIF. Exposure of RCC10/VHL cells to hypoxia for 48
hrs resulted in a significant increase in mRNA levels of
NMU compared to normoxic cultures (Figure 2). In a
second approach, we activated HIF in the presence of
VHL, using dimethyloxalylglycine (DMOG), a cell
permeable 2-oxyglutarate-dependent dioxygenase inhibi-
tor which inhibits the PHD enzymes. Treatment with
DMOG resulted in a striking induction of both NMU
mRNA compared to untreated cells (Figure 2). These
results would be consistent with HIF activation mediat-
ing increased NMU expression in VHL defective
CCRCC cells.
To further investigate the ability of HIF to mediate
NMU expression we studied the effect of VHL missense
mutants, L188V and V84L. These single amino acid sub-
stitutions are associated clinically with phaeochromocy-
toma, but not with other tumours (type 2C VHL
disease) and retain the ability to regulate HIF [20]. Ana-
lysis by real time RT-PCR showed a marked mRNA
suppression of NMU in cell pools expressing either wild
type VHL or type 2C mutant VHL, in both RCC10 and
RCC4 cells (Figure 3A). The concordance between the
ability of VHL mutants to suppress both HIF and NMU
levels supports the notion that HIF activation underlies
the VHL defective phenotype. Next we used a direct
genetic approach to determine the role of HIF. RCC10
and RCC4 VHL defective cells were transfected with
previously validated siRNAs to selectively suppress
either HIF-1a or HIF-2a, or with a control siRNA.
Knock-down of either HIF-a isoform resulted in
decreased expression of NMU in both cell backgrounds
(Figure 3B). Taken together these findings provide
strong evidence that VHL regulates NMU expression in
renal cancer cells via HIF.
Next we asked whether NMU contains a HIF binding
site, known as a hypoxia response element (HRE). A 12
kb segment upstream of the transcriptional start site
and the first intron (3 kb) were analysed. Although this
region contains several candidate HREs, none were
found to be responsive to HIF activation as assessed by
increased luciferase reporter activity. There are three
possible explanations for this. First, the region may con-
tain a functional HRE but the transfection assays did
not provide requisite conditions to detect this. This pos-
sibility is lessened because we used different approaches
to activate HIF (DMOG or co-transfection with a plas-
mid expressing constitutively active HIF), different cell
Figure 2 Neuromedin U is upregulated by hypoxia and DMOG in VHL expressing CCRCC cell lines. RCC10/VHL and RCC4/VHL cell were
exposed to either 1% hypoxia in a hypoxic Galaxy R incubator (Biotech, Palo Alto, CA) or 1 mM dimethyl-oxalylglycine (DMOG; Frontier
Bioscientific, Logan, UT) for 48 hours. Western analysis showed marked upregulation of both HIF-1a and HIF-2a in treated cell lines. Levels of
NMU and the HIF target gene PHD3 were found to be significantly upregulated using real-time RT PCR analysis (*p < 0.01 using Student’s t test).
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lines, and all experiments were accompanied by controls
using an HRE which confirmed a high amplitude HIF
response. Second, there may be an HRE which lies out-
side this region; a precedent for this is the prototypical
HRE which actually lies 3’ to the EPO gene [21]. Third,
the effect of HIF may be indirect.
NMU is believed to act mainly in a paracrine fashion,
and autocrine signalling has been suggested in several
cancer settings [13]. To determine whether renal cancer
cells might respond to NMU we first examined expres-
sion of the receptors NMUR1 and NMUR2. Western
analysis showed that NMUR1 was expressed in both the
RCC4 and RCC10 cell backgrounds and that there was
no substantial effect of VHL status on expression levels
(Figure 4A). Expression of NMUR2 was not detected
(data not shown). Previous studies have reported that
NMU receptor binding triggers the mobilisation of
intracellular calcium [13]. Renal cancer cells and sub-
lines expressing VHL (RCC10, RCC4, RCC10/VHL,
RCC4/VHL) were loaded with a calcium sensitive fluor-
escent dye prior to treatment with exogenous NMU
peptide. Addition of NMU caused a sharp calcium
influx in all cell lines, regardless of VHL status, whereas
addition of vehicle alone caused no significant change.
A representative FLIPR trace is shown in Figure 4B.
Given that these experiments show that an NMU
response pathway is present in renal cancer cells, we
next investigated the potential functional role of NMU
in these cells.
Proliferation and tissue invasion and metastasis are
two hallmarks of cancer that have been associated with
NMU expression in other cell types [14,22,23]. First we
tested the effect of NMU on proliferation. Exogenous
NMU peptide was added to RCC10/VHL cells; no effect
on cell growth was observed (data not shown). Next we
tested the ability of NMU to promote migration and
invasion of renal cancer cells. RCC10/VHL retroviral cell
pools expressing either an empty vector or NMU were
prepared and NMU expression was verified by real-time
RT-PCR. To assess migration, cells were serum starved
for 24 hours, fluorescently labelled and then plated onto
the upper section of a transwell chamber in serum free
Figure 3 Suppression of HIF-a subunits in RCC10 and RCC4 CCRCC cell lines decreases NMU expression. A) VHL Type 2C mutants
suppress HIF and NMU: Retroviral RCC10 and RCC4 cell pools expressing either wild-type VHL (VHL30), a type 2C mutant VHL (either VHL L188V or
VHL V84L) or an empty vector were prepared as described previously [7]. Expression of VHL was confirmed by Western blotting. Analysis of HIF-a
subunit expression showed that levels of both HIF-1a and HIF-2a were suppressed in cell pools expressing either wild-type VHL or type 2C
mutant VHL. NMU expression was significantly decreased in RCC10 and RCC4 cell lines expressing either wild-type or type 2C mutant VHLs, but
not an empty vector control. B) Suppression of HIF via siRNA of HIF-a subunits results in down-regulation of NMU: RCC10 and RCC4 cells were
transfected with a control siRNA (firefly luciferase) or siRNA oligos targeting HIF-1a or HIF-2a using LipofectAMINE 2000 (Invitrogen, Carlsbad,
CA). (Oligos: Firelfly Luciferase 5’-CGUACGCGGAAUACUUCGAdTdT-3’ (sense), 5’-AAGCUAAAGGUACACAAUUdTdT-3’ (antisense); HIF-1a 5’-
CUGAUGACCAGCAACUUGAdTdT-3’ (sense), 5’-UCAAGUUGCUGGUCAUCAGdTdT-3’ (antisense); HIF-2a 5’-CAGCAUCUUUGAUAGCAGUdTdT-3’
(sense), 5’-ACUGCUAUCAAAGAUGCUGdTdT-3’ (antisense). Cells were plated in duplicate and harvested 48 hours post transfection for either RNA
or protein. Western blotting for HIF-1a and HIF-2a confirmed selective and efficient knock-down of the targeted HIF-a subunit. Real-time RT PCR
showed that HIF-a knock-down significantly suppressed NMU expression in both RCC4 and RCC10 cells. *p < 0.01, using Student’s t test.
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media. The number of cells that migrated through the
membrane was recorded. Invasion assays were per-
formed by plating serum-starved cells onto matrigel
coated transwell chambers in serum free media. After
24 hours, cells were removed from the top layer and
invasive cells on the bottom layer were fixed, stained
with Giemsa and counted. Data from three independent
experiments and representative photomicrographs are
shown in Figure 4C and 4D. Thus expression of NMU
was found to significantly enhance both cell migration
and invasion of RCC10/VHL cells.
Next, we searched the Gene Expression Omnibus
database (GEO, http://www.ncbi.nlm.nih.gov/geo/) for
publicly available microarray datasets comparing gene
Figure 4 The NMU pathway is functionally active in renal cancer cells and contributes to a migratory and invasive phenotype. A)
Western blotting showed that NMUR1 is expressed in CCRCC cells. B) NMU peptide induces a calcium flux in renal cancer cells: RCC cell cultures
were loaded with a calcium sensitive dye (fluo-4 AM; Invitrogen, Carlsbad, CA) and washed with HBSS. A fluorometric imaging plate reader
(FLIPR; Molecular Devices, Sunnyvale, CA) recorded fluorescence (lEX = 488 nm, lEM = 540 nm) before and after robotic addition of 60 μL of
NMU peptide (final concentration = 300 μM) or a vehicle control. A representative trace from RCC10/VHL cells is shown. RCC10, RCC4 and RCC4/
VHL cells all showed similar results. Significance was determined by analysing peak fluorescence induction in NMU treated and untreated cells
from five independent experiments. C & D) Constitutive expression of NMU promotes cell migration and invasion: Retroviral cell pools expressing
either NMU or an empty vector were prepared in RCC10/VHL cells. Cells were serum-starved, fluorescently labelled (migration assay only) and
plated onto the upper compartment of FluoroBlok transwell migration chambers (C) or matrigel BioCoat transwell invasion chambers (D). Media
with 5% FCS was added to the lower compartment. After 9 hours (migration assays) or 24 hours (invasion assays) cells were fixed. Invasion
membranes were stained with Giemsa. Cells were counted in five fields. RCC10/VHL cells expressing NMU showed significantly more migration
and invasion than empty vector control cells (*p < 0.05, Student’s t test, three independent experiments).
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expression in normal human kidney tissues to CCRCC
tissues. Three relevant datasets were identified. Analysis
of data from Gumz et al. showed a > 2 fold upregula-
tion of NMU in 5/10 pairs of matched normal kidney
and tumour tissue from patients with sporadic CCRCCs
(Additional File 1a) [24]. Analysis of two larger, inde-
pendent datasets comparing unmatched normal kidney
and CCRCC tissues, GSE15641 and GSE14994, also
showed > 2 fold upregulation of NMU in 46.9% and
11.9% of CCRCCs, respectively, compared to the mean
expression in normal kidney (Additional File 1b and 1c)
[25,26]. These results are consistent with NMU expres-
sion being substantially increased in a subset of human
CCRCCs.
Loss of functional VHL has previously been shown to
enhance migration and invasion [27]. Here we demon-
strate an autocrine NMU pathway in renal cancer cells
that likely contributes to promoting migration of VHL
expressing cells. This adds to evidence for a role of
NMU in diverse cancers including bladder carcinoma
[22], ovarian carcinoma [28], lung cancer [23] and acute
myeloid leukaemia [13]. It also raises the possibility that
HIF activation, for example at altitude, could increase
physiological NMU signalling in the brain causing loss
of appetite.
Additional material
Additional File 1: External data sets show a subset of clear cell
renal carcinomas with upregulation of NMU compared to normal
kidney. Publicly available microarray datasets comparing expression in
normal human kidney tissue to CCRCC tissues were interrogated for
NMU expression. A) A scatter plot showing NMU expression in matched
normal and tumour tissue samples from patients with sporadic CCRCCs
(GDS2880; [24]). 5/10 pairs show > 2 fold upregulation of NMU (data
points shown in red). B), C) Scatterplots show fold upregulation of NMU
in normal kidney and CCRCC tissue samples compared to the mean
expression level detected in normal kidneys in two external datasets,
GSE15641 [26] and GSE14994 [25]. Data points in red show > 2 fold
upregulation (GSE15641, 15/32 (46.9%) CCRCC samples show >2 fold
upregulation; GSE14994, 7/59 (11.9%) of CCRCC samples show >2 fold
upregulation). Normalised data available from GEO was used for all
analyses.
List of abbreviations
CCRCC: clear cell renal cell carcinoma; FLIPR: fluorometric imaging plate
reader; GEO: Gene Expression Omnibus; HIF: hypoxia-inducible factor; HRE:
hypoxia response element; DMOG: dimethyl-oxalylglycine; NMU:
Neuromedin U; PHD: prolyl hydroxylase domain; VHL: von Hippel-Lindau.
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